Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Oesophago-gastric Cancer × Epirubicin × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 29 Esophageal Neoplasms 14 Carcinoma, Hepatocellular 14 Pancreatic Neoplasms 4 Liver Neoplasms 4 Gallbladder Neoplasms 3 Adenocarcinoma Of Esophagus 3 Neoplasm Metastasis 2 Bile Duct Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 1 Salivary Gland Neoplasms 1 Recurrence 1 Pathologic Complete Response 1 Oesophagogastric Cancer 1 Oesophago-gastric Cancer 1 Neoplastic Cells, Circulating 1 Neoplasms 1 Metastatic Advanced Gastric Cancer 1 Head and Neck Neoplasms 1 Gastro Oesophageal Cancer 1 Esthesioneuroblastoma, Olfactory 1 Esophageal Squamous Cell Carcinoma 1 Colonic Neoplasms 1 CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction 1 Biliary Tract Neoplasms 1 Advanced Gastric Cancer 1 Adenocarcinoma of the Esophagogastric Junction 1 Adenocarcinoma 1

Interventions

Panitumumab 1 Oxaliplatin 1 Epirubicin 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00824785 2012-12-11

REAL3

Royal Marsden NHS Foundation Trust

Phase 3 Terminated

Gastrointestinal

Oesophago-gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡